Role of a novel risk loci HAVCR2 of late-onset Alzheimer's disease in the regulation of microglial response in neurodegeneration
迟发性阿尔茨海默病的新风险位点 HAVCR2 在调节神经退行性小胶质细胞反应中的作用
基本信息
- 批准号:10608400
- 负责人:
- 金额:$ 83.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmyloid beta-Protein PrecursorAnimal ModelAntibodiesAntigen PresentationAntigensAreaAutoimmune DiseasesBasic ScienceBehaviorBindingBlocking AntibodiesBrainCell physiologyChronicCognitiveDataDementiaDendritic CellsDepositionDevelopmentDiseaseDisease ProgressionDisease associated microgliaGeneticGoalsHumanImmunityInvestigationLaboratoriesLate Onset Alzheimer DiseaseLigandsLinkMaintenanceMalignant NeoplasmsMicrogliaModelingMusMyeloid Cell ActivationMyeloid CellsNatural ImmunityNerve DegenerationNeurodegenerative DisordersOnset of illnessOutcomePathologyPhagocytesPhagocytosisPhenotypePhosphorylationPlayReceptor SignalingRegulationRoleSignal InductionSignal TransductionT-LymphocyteTGFB1 geneTauopathiesTranscriptTranslatingTumor ImmunityViral CancerVirus DiseasesWorkaging braincancer clinical trialcancer therapycytokinedrug candidateexhaustiongenetic linkagegenetic risk factorgenome wide association studyglial activationimmunoregulationimprovedinduced pluripotent stem cellmouse modelneuroinflammationnovelnovel therapeutic interventionpharmacologicresponserestraintrisk variantsynergismtherapy development
项目摘要
PROJECT SUMMARY
Recent largest GWAS identified HAVCR2 (TIM3) genetic risk factor for late-onset Alzheimer’s disease (LOAD).
Our laboratory discovered and cloned Tim3 as an inhibitory molecule that induces T cell exhaustion in cancer1.
Blocking antibodies to Tim3 are being approved for the treatment of cancer. However, we have now identified
that Tim3 is not only expressed on T cells, but also on myeloid cells and dendritic cells, where TIM3 restrains
dendritic cell function and regulate anti-tumor immunity2. In the CNS, HAVCR2 was identified as one of the top
100 enriched transcripts and is specifically expressed in both mouse and human microglia3-5, but its role and
function in microglia is unknown.
Our long-term goal is to define the role of TIM3 in regulation of microglia in neurodegeneration. We made the
following observations: 1) Tim3 inhibits microglial activation and phagocytosis: deletion of Tim3 in dendritic
cells boosted antigen presentation and we find that TIM3 also regulates microglial activation and phagocytosis;
2) TGFb-Tim3 axis regulates microglia phenotype switch in neurodegeneration: we find that TGFb is the key
driver for the induction of Tim3 and once expressed it synergizes with TGFBR to potentiate TGFB signaling, loss
of Tim3 switches M0-homeostatic microglia to an MGnD-nondegenerative phenotype; and 3) TIM3 deletion in
microglia reduces plaque burden in 5xFAD mice. These data support the genetic linkage studies and show the
importance of Tim3 in regulating disease pathology in AD by modulating microglial function. Based on these
studies, we hypothesize that TIM3 is a key regulatory molecule in microglia that inhibits their response
to neurodegeneration, migratory and phagocytic functions and thereby inhibit plaque clearance
resulting in promotion of Ab deposition, development, and progression of AD in aging brain. Based on
this hypothesis we have proposed three aims:
Aim 1: Define how TIM3 regulates phenotype and functions in 5xFAD and P301S mouse AD models. We
propose to study the effect of microglial deletion of Tim3 in neurodegeneration and brain tauopathy using the
mouse models of AD.
Aim 2: What is the role of TGFb signaling in the regulation of Tim3 expression and function in microglia
and development of AD? Since TGFb plays a critical role in maintenance of the homeostatic phenotype in
microglia, we propose to study how TGFb signaling induces Tim3 expression and promotes homeostatic
behavior of microglia by cooperating with TGFb receptor signaling.
Aim 3: Define the role of TIM3 in the regulation of human microglial function in AD. Determine how TIM3
impacts human iPSC-derived microglia activation and functions. We will examine whether genetic or
pharmacologic inhibition of TIM3 has a similar effect on iPSCs-derived human microglia expressing the MGnD
phenotype by utilizing a humanized chimeric mouse model of AD for treatment with human anti-Tim3 antibody
IN SUMMARY, targeting TIM3 in microglia may provide a novel approach for therapeutic modulation of innate
immunity in AD and dementia.
项目摘要
最近最大的GWAS确定了晚发性阿尔茨海默病(LOAD)的HAVCR 2(TIM 3)遗传风险因子。
我们的实验室发现并克隆了Tim 3作为一种抑制性分子,可诱导癌症中的T细胞耗竭1。
Tim 3的阻断抗体已被批准用于治疗癌症。然而,我们现在已经确定
Tim 3不仅在T细胞上表达,而且在骨髓细胞和树突状细胞上也表达,其中TIM 3抑制
树突状细胞功能和调节抗肿瘤免疫2.在中枢神经系统中,HAVCR 2被鉴定为最重要的免疫调节因子之一。
100个富集的转录物,并在小鼠和人小胶质细胞中特异性表达3 -5,但其作用和
小胶质细胞的功能尚不清楚。
我们的长期目标是确定TIM 3在神经变性中调节小胶质细胞的作用。我们做出了
以下观察:1)Tim 3抑制小胶质细胞活化和吞噬作用:树突状细胞中Tim 3的缺失
细胞促进抗原呈递,我们发现TIM 3也调节小胶质细胞活化和吞噬作用;
2)TGFb-Tim 3轴调节神经退行性变中小胶质细胞表型转换:我们发现TGFb是关键
Tim 3是诱导Tim 3的驱动因子,一旦表达,它就与TGFBR协同作用,增强TGFB信号传导,
Tim 3的缺失将M0-稳态小胶质细胞转换为MGnD-非变性表型;以及3)在MGnD-非变性表型中的TIM 3缺失。
小胶质细胞减少5xFAD小鼠中的斑块负荷。这些数据支持遗传连锁研究,并显示
Tim 3在通过调节小胶质细胞功能调节AD疾病病理中的重要性。基于这些
研究中,我们假设TIM 3是小胶质细胞中抑制其反应的关键调节分子,
神经变性、迁移和吞噬功能,从而抑制斑块清除
导致在老化脑中促进Ab沉积、发展和AD进展。基于
这个假设我们提出了三个目标:
目的1:确定TIM 3如何调节5xFAD和P301 S小鼠AD模型的表型和功能。我们
我们建议使用神经元变性和脑tau蛋白病来研究Tim 3的小胶质细胞缺失的作用。
AD小鼠模型。
目的2:TGF β信号通路在小胶质细胞Tim 3表达和功能调控中的作用
发展AD?由于TGF β在维持体内稳态表型中起关键作用,
小胶质细胞,我们建议研究TGF β信号如何诱导Tim 3表达,并促进稳态
通过与TGF β受体信号传导合作来调节小胶质细胞的行为。
目的3:明确TIM 3在AD患者小胶质细胞功能调节中的作用。确定TIM 3
影响人类iPSC衍生的小胶质细胞活化和功能。我们将研究是否遗传或
TIM 3的药理学抑制对表达MGnD的iPSC衍生的人小胶质细胞具有类似的作用
通过利用AD的人源化嵌合小鼠模型用人抗Tim 3抗体治疗表型
总之,靶向小胶质细胞中的TIM 3可能为治疗性调节先天性巨噬细胞凋亡提供一种新的方法。
AD和痴呆症中的免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oleg Butovsky其他文献
Oleg Butovsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Oleg Butovsky', 18)}}的其他基金
Gender-dependent APOE4 regulation of neutrophil-microglia crosstalk in Alzheimer's disease
阿尔茨海默病中中性粒细胞-小胶质细胞串扰的性别依赖性 APOE4 调节
- 批准号:
10552667 - 财政年份:2022
- 资助金额:
$ 83.13万 - 项目类别:
Gender-dependent APOE4 regulation of neutrophil-microglia crosstalk in Alzheimer's disease
阿尔茨海默病中中性粒细胞-小胶质细胞串扰的性别依赖性 APOE4 调节
- 批准号:
10344242 - 财政年份:2022
- 资助金额:
$ 83.13万 - 项目类别:
APOE e4 negative regulation of microglia-astrocytes crosstalk in Alzheimer's disease
APOE e4 对阿尔茨海默病中小胶质细胞-星形胶质细胞串扰的负调节
- 批准号:
10429190 - 财政年份:2022
- 资助金额:
$ 83.13万 - 项目类别:
Xenon gas treatment to modulate microglia in neurodegenerative diseases
氙气治疗调节神经退行性疾病中的小胶质细胞
- 批准号:
10617078 - 财政年份:2021
- 资助金额:
$ 83.13万 - 项目类别:
Xenon gas treatment to modulate microglia in neurodegenerative diseases
氙气治疗调节神经退行性疾病中的小胶质细胞
- 批准号:
10259094 - 财政年份:2021
- 资助金额:
$ 83.13万 - 项目类别:
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer's disease
靶向 miR-155 和 APOE-TREM2 通路以恢复阿尔茨海默病中功能失调的小胶质细胞
- 批准号:
9926784 - 财政年份:2017
- 资助金额:
$ 83.13万 - 项目类别:
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s disease
靶向 miR-155 和 APOE-TREM2 通路以恢复阿尔茨海默病中功能失调的小胶质细胞
- 批准号:
9219386 - 财政年份:2017
- 资助金额:
$ 83.13万 - 项目类别:
Microglial mechanisms of postoperative CNS inflammation and cognitive decline
术后中枢神经系统炎症和认知能力下降的小胶质细胞机制
- 批准号:
9010611 - 财政年份:2016
- 资助金额:
$ 83.13万 - 项目类别:
Restoration of homeostatic microglia in CNS inflammation
中枢神经系统炎症中小胶质细胞稳态的恢复
- 批准号:
10426253 - 财政年份:2014
- 资助金额:
$ 83.13万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 83.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 83.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 83.13万 - 项目类别: